Is It Possible to Predict the Future in First-Episode Psychosis?
Open accessThe DOI matches its Crossref record; 49 of the 49 references it cites were found in a registry or an index.
Abstract
The outcome of first-episode psychosis (FEP) is highly variable, ranging from early sustained recovery to antipsychotic treatment resistance from the onset of illness. For clinicians, a possibility to predict patient outcomes would be highly valuable for the selection of antipsychotic treatment and in tailoring psychosocial treatments and psychoeducation. This selective review summarizes current knowledge of prognostic markers in FEP. We sought potential outcome predictors from clinical and sociodemographic factors, cognition, brain imaging, genetics, and blood-based biomarkers, and we considered different outcomes, like remission, recovery, physical comorbidities, and suicide risk. Based on the review, it is currently possible to predict the future for FEP patients to some extent. Some clinical features-like the longer duration of untreated psychosis (DUP), poor premorbid adjustment, the insidious mode of onset, the greater severity of negative symptoms, comorbid substance use disorders (SUDs), a history of suicide attempts and suicidal ideation and having non-affective psychosis-are associated with a worse outcome. Of the social and demographic factors, male gender, social disadvantage, neighborhood deprivation, dysfunctional family environment, and ethnicity may be relevant. Treatment non-adherence is a substantial risk factor for relapse, but a small minority of patients with acute onset of FEP and early remission may benefit from antipsychotic discontinuation. Cognitive functioning is associated with functional outcomes. Brain imaging currently has limited utility as an outcome predictor, but this may change with methodological advancements. Polygenic risk scores (PRSs) might be useful as one component of a predictive tool, and pharmacogenetic testing is already available and valuable for patients who have problems in treatment response or with side effects. Most blood-based biomarkers need further validation. None of the currently available predictive markers has adequate sensitivity or specificity used alone. However, personalized treatment of FEP will need predictive tools. We discuss some methodologies, such as machine learning (ML), and tools that could lead to the improved prediction and clinical utility of different prognostic markers in FEP. Combination of different markers in ML models with a user friendly interface, or novel findings from e.g., molecular genetics or neuroimaging, may result in computer-assisted clinical applications in the near future.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Machine learning: Trends, perspectives, and prospects
Jordan, M. I., & Mitchell, T. M. (2015) · Science · doi:10.1126/science.aaa8415 · Cited by 9,955
Deo, R. C. (2015) · Circulation · doi:10.1161/circulationaha.115.001593 · Cited by 3,466
Leucht, S., Cipriani, A., Spineli, L., Mavridis, D., Örey, D., Richter, F., Samara, M., Barbui, C., Engel, R. R., Geddes, J. R., et al. (2013) · The Lancet · doi:10.1016/s0140-6736(13)60733-3 · Cited by 2,561
Lichtenstein, P., Yip, B. H., Björk, C., Pawitan, Y., Cannon, T. D., Sullivan, P. F., & Hultman, C. M. (2009) · The Lancet · doi:10.1016/s0140-6736(09)60072-6 · Cited by 2,125
Analysis of shared heritability in common disorders of the brain
The Brainstorm Consortium, Anttila, V., Bulik-Sullivan, B., Finucane, H. K., Walters, R. K., Bras, J., Duncan, L., Escott-Price, V., Falcone, G. J., Gormley, P., et al. (2018) · Science · doi:10.1126/science.aap8757 · Cited by 1,924
Fett, A.-K. J., Viechtbauer, W., Dominguez, M.-D.-G., Penn, D. L., van Os, J., & Krabbendam, L. (2011) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2010.07.001 · Cited by 1,833
Meta-Analysis of Cytokine Alterations in Schizophrenia: Clinical Status and Antipsychotic Effects
Miller, B. J., Buckley, P., Seabolt, W., Mellor, A., & Kirkpatrick, B. (2011) · Biological Psychiatry · doi:10.1016/j.biopsych.2011.04.013 · Cited by 1,742
Goldsmith, D. R., Rapaport, M. H., & Miller, B. J. (2016) · Molecular Psychiatry · doi:10.1038/mp.2016.3 · Cited by 1,683
GERAD1 Consortium, Pardiñas, A. F., CRESTAR Consortium, Holmans, P., Pocklington, A. J., Escott-Price, V., Ripke, S., Carrera, N., Legge, S. E., Bishop, S., et al. (2018) · Nature Genetics · doi:10.1038/s41588-018-0059-2 · Cited by 1,552
Premature Mortality Among Adults With Schizophrenia in the United States
Olfson, M., Gerhard, T., Huang, C., Crystal, S., & Stroup, T. S. (2015) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2015.1737 · Cited by 1,083
Contribution of copy number variants to schizophrenia from a genome-wide study of 41,321 subjects
Marshall, C. R., Howrigan, D. P., Merico, D., Thiruvahindrapuram, B., Wu, W., Greer, D. S., Antaki, D., Shetty, A., Holmans, P. A., Pinto, D., et al. (2017) · Nature Genetics · doi:10.1038/ng.3725 · Cited by 1,058 · cited 2×
“The Psychiatric Genomics Consortium recently validated six deletions and two duplications of significant risk factors for schizophrenia, and identified several novel ones (94).”
Self-citationOrrù, G., Pettersson-Yeo, W., Marquand, A. F., Sartori, G., & Mechelli, A. (2012) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2012.01.004 · Cited by 1,012
Strategic roadmap for an early diagnosis of Alzheimer's disease based on biomarkers
Frisoni, G. B., Boccardi, M., Barkhof, F., Blennow, K., Cappa, S., Chiotis, K., Démonet, J.-F., Garibotto, V., Giannakopoulos, P., Gietl, A., et al. (2017) · The Lancet Neurology · doi:10.1016/s1474-4422(17)30159-x · Cited by 626
Comorbidities and mortality in persons with schizophrenia: a Swedish national cohort study
Crump, C., Winkleby, M. A., Sundquist, K., & Sundquist, J. (2013) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2012.12050599 · Cited by 619
An Individualized Risk Calculator for Research in Prodromal Psychosis
Cannon, T. D., Yu, C., Addington, J., Bearden, C. E., Cadenhead, K. S., Cornblatt, B. A., Heinssen, R., Jeffries, C. D., Mathalon, D. H., McGlashan, T. H., et al. (2016) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2016.15070890 · Cited by 574 · cited 3×
“As an example, a risk calculator for predicting the psychosis conversion risk in patients with a clinical high-risk state was recently published (181).”
BackgroundInfluentialWunderink, L., Nieboer, R. M., Wiersma, D., Sytema, S., & Nienhuis, F. J. (2013) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2013.19 · Cited by 567
van der Meer, L., Costafreda, S., Aleman, A., & David, A. S. (2010) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2009.12.004 · Cited by 520 · cited 1×
“Insight and Resilience Insight has been of special interest as a predictor of the outcome of FEP, as defects in insight may possibly arise from the same functional and structural brain pathology as psychosis itself (23, 24).”
BackgroundAlvarez-Jimenez, M., Priede, A., Hetrick, S. E., Bendall, S., Killackey, E., Parker, A. G., McGorry, P. D., & Gleeson, J. F. (2012) · Schizophrenia Research · doi:10.1016/j.schres.2012.05.007 · Cited by 511
Cytokine function in medication-naive first episode psychosis: A systematic review and meta-analysis
Upthegrove, R., Manzanares-Teson, N., & Barnes, N. M. (2014) · Schizophrenia Research · doi:10.1016/j.schres.2014.03.005 · Cited by 501
Study, S. S., Singh, T., Study, I., Study, D., UK10 K Consortium, Kurki, M. I., Curtis, D., Purcell, S. M., Crooks, L., McRae, J., et al. (2016) · Nature Neuroscience · doi:10.1038/nn.4267 · Cited by 452
Self-citationRidker, P. M. (2016) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2015.11.037 · Cited by 414
Correll, C. U., Robinson, D. G., Schooler, N. R., Brunette, M. F., Mueser, K. T., Rosenheck, R. A., Marcy, P., Addington, J., Estroff, S. E., Robinson, J., et al. (2014) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2014.1314 · Cited by 384
Fernandes, B. S., Steiner, J., Bernstein, H.-G., Dodd, S., Pasco, J. A., Dean, O. M., Nardin, P., Gonçalves, C.-A., & Berk, M. (2016) · Molecular Psychiatry · doi:10.1038/mp.2015.87 · Cited by 348
Lally, J., Ajnakina, O., Stubbs, B., Cullinane, M., Murphy, K. C., Gaughran, F., & Murray, R. M. (2017) · British Journal of Psychiatry · doi:10.1192/bjp.bp.117.201475 · Cited by 335
Velligan, D. I., Sajatovic, M., Hatch, A., Kramata, P., & Docherty, J. (2017) · Patient Preference and Adherence · doi:10.2147/ppa.s124658 · Cited by 333 · cited 1×
“Poor insight may prolong the DUP (32) and predict non-adherence to medication treatment in FEP patients (33), although the results in prospective studies with FEP samples are somewhat mixed with regards to treatment adherence (34).”
ResultSchoeler, T., Monk, A., Sami, M. B., Klamerus, E., Foglia, E., Brown, R., Camuri, G., Altamura, A. C., Murray, R., & Bhattacharyya, S. (2016) · The Lancet Psychiatry · doi:10.1016/s2215-0366(15)00363-6 · Cited by 322
Evaluating historical candidate genes for schizophrenia
Farrell, M. S., Werge, T., Sklar, P., Owen, M. J., Ophoff, R. A., O'Donovan, M. C., Corvin, A., Cichon, S., & Sullivan, P. F. (2015) · Molecular Psychiatry · doi:10.1038/mp.2015.16 · Cited by 315 · cited 1×
“However, recent genetic studies have questioned the validity of previously suggested schizophrenia candidate genes (81, 82).”
BackgroundLally, J., Ajnakina, O., Di Forti, M., Trotta, A., Demjaha, A., Kolliakou, A., Mondelli, V., Reis Marques, T., Pariante, C., Dazzan, P., et al. (2016) · Psychological Medicine · doi:10.1017/s0033291716002014 · Cited by 298 · cited 10×
“The majority of treatmentresistant patients are treatment resistant from the onset of illness (4, 22).”
BackgroundInfluentialFillman, S. G., Weickert, T. W., Lenroot, R. K., Catts, S. V., Bruggemann, J. M., Catts, V. S., & Weickert, C. S. (2016) · Molecular Psychiatry · doi:10.1038/mp.2015.90 · Cited by 270
Reappraising the long-term course and outcome of psychotic disorders: the AESOP-10 study
Morgan, C., Lappin, J., Heslin, M., Donoghue, K., Lomas, B., Reininghaus, U., Onyejiaka, A., Croudace, T., Jones, P. B., Murray, R. M., et al. (2014) · Psychological Medicine · doi:10.1017/s0033291714000282 · Cited by 248
Lysaker, P. H., Pattison, M. L., Leonhardt, B. L., Phelps, S., & Vohs, J. L. (2018) · World Psychiatry · doi:10.1002/wps.20508 · Cited by 247
Perkins, D. O., Jeffries, C. D., Addington, J., Bearden, C. E., Cadenhead, K. S., Cannon, T. D., Cornblatt, B. A., Mathalon, D. H., McGlashan, T. H., Seidman, L. J., et al. (2015) · Schizophrenia Bulletin · doi:10.1093/schbul/sbu099 · Cited by 238 · cited 2×
“Of note is that, while the profile of analytes were fairly similar in these two studies, only three individual analytes (interleukin 8, thyroid stimulating hormone, and factor VII) were the same in both panels (138, 139).”
BackgroundMethodSingh, T., Walters, J. T. R., Johnstone, M., Curtis, D., Suvisaari, J., Torniainen, M., Rees, E., Iyegbe, C., Blackwood, D., McIntosh, A. M., et al. (2017) · Nature Genetics · doi:10.1038/ng.3903 · Cited by 231
Self-citationPillinger, T., D’Ambrosio, E., McCutcheon, R., & Howes, O. D. (2019) · Molecular Psychiatry · doi:10.1038/s41380-018-0058-9 · Cited by 230 · cited 2×
“In drug-naïve FEP patients, there is evidence for an increased level of morning cortisol, cortisol awakening response, and increased prolactin levels, all of which may refer to a dysregulated hypothalamic-pituitary-adrenal (HPA) axis (130).”
BackgroundKendall, K. M., Rees, E., Escott-Price, V., Einon, M., Thomas, R., Hewitt, J., O’Donovan, M. C., Owen, M. J., Walters, J. T. R., & Kirov, G. (2017) · Biological Psychiatry · doi:10.1016/j.biopsych.2016.08.014 · Cited by 226 · cited 1×
“risk of schizophrenia in case-control studies (94), general population-based studies have also identified people carrying the same CNVs who have normal functioning and only minimal problems in cognitive tests (95).”
BackgroundAntipsychotic treatment and mortality in schizophrenia.
Torniainen, M., Mittendorfer-Rutz, E., Tanskanen, A., Bjorkenstam, C., Suvisaari, J., Alexanderson, K., & Tiihonen, J. (2015) · Schizophrenia Bulletin · doi:10.1093/schbul/sbu164 · Cited by 208 · cited 1×
“Antipsychotic use is associated with a lower mortality risk in several studies (23, 163), but using doses of antipsychotics that exceed the recommended dose may increase CVD mortality (164).”
BackgroundSelf-citationOsborn, D. P. J., Hardoon, S., Omar, R. Z., Holt, R. I. G., King, M., Larsen, J., Marston, L., Morris, R. W., Nazareth, I., Walters, K., et al. (2015) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2014.2133 · Cited by 200
Prins, B. P., Abbasi, A., Wong, A., Vaez, A., Nolte, I., Franceschini, N., Stuart, P. E., Guterriez Achury, J., Mistry, V., Bradfield, J. P., et al. (2016) · PLOS Medicine · doi:10.1371/journal.pmed.1001976 · Cited by 199
Reassessing the long-term risk of suicide after a first episode of psychosis
Dutta, R., Murray, R. M., Hotopf, M., Allardyce, J., Jones, P. B., & Boydell, J. (2010) · Archives of General Psychiatry · doi:10.1001/archgenpsychiatry.2010.157 · Cited by 190
Neuropathology of suicide: Recent findings and future directions
Lutz, P.-E., Mechawar, N., & Turecki, G. (2017) · Molecular Psychiatry · doi:10.1038/mp.2017.141 · Cited by 158
Czobor, P., Van Dorn, R. A., Citrome, L., Kahn, R. S., Fleischhacker, W. W., & Volavka, J. (2015) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2015.04.003 · Cited by 112 · cited 1×
“Poor insight may prolong the DUP (32) and predict non-adherence to medication treatment in FEP patients (33), although the results in prospective studies with FEP samples are somewhat mixed with regards to treatment adherence (34).”
ResultPredictors of Relapse and Functioning in First-Episode Psychosis: A Two-Year Follow-Up Study
Bergé, D., Mané, A., Salgado, P., Cortizo, R., Garnier, C., Gomez, L., Diez-Aja, C., Bulbena, A., & Pérez, V. (2016) · Psychiatric Services · doi:10.1176/appi.ps.201400316 · Cited by 96
Polygenic Risk Score for Schizophrenia and Treatment-Resistant Schizophrenia
Wimberley, T., Gasse, C., Meier, S. M., Agerbo, E., MacCabe, J. H., & Horsdal, H. T. (2017) · Schizophrenia Bulletin · doi:10.1093/schbul/sbx007 · Cited by 89 · cited 1×
“One fairly large study, however, failed to find an association between PRS and poor treatment response in schizophrenia (89).”
BackgroundTruncating mutations in RBM12 are associated with psychosis
Steinberg, S., Gudmundsdottir, S., Sveinbjornsson, G., Suvisaari, J., Paunio, T., Torniainen-Holm, M., Frigge, M. L., Jonsdottir, G. A., Huttenlocher, J., Arnarsdottir, S., et al. (2017) · Nature Genetics · doi:10.1038/ng.3894 · Cited by 70 · cited 1×
“In exome and whole-genome sequencing studies, the first rare mutations in single genes that are associated with a substantially increased schizophrenia risk have been identified (96, 97).”
BackgroundSelf-citationVohs, J. L., George, S., Leonhardt, B. L., & Lysaker, P. H. (2016) · Expert Review of Neurotherapeutics · doi:10.1080/14737175.2016.1199275 · Cited by 66 · cited 1×
“Impaired clinical insight, which is somewhat separable from cognitive insight, has been associated with poorer social functioning, more re-hospitalizations and treatment nonadherence (30).”
BackgroundThompson, A., Winsper, C., Marwaha, S., Haynes, J., Alvarez-Jimenez, M., Hetrick, S., Realpe, A., Vail, L., Dawson, S., & Sullivan, S. A. (2018) · BJPsych Open · doi:10.1192/bjo.2018.17 · Cited by 44
Drake, R. J., Nordentoft, M., Haddock, G., Arango, C., Fleischhacker, W. W., Glenthøj, B., Leboyer, M., Leucht, S., Leweke, M., McGuire, P., et al. (2015) · Schizophrenia Bulletin · doi:10.1093/schbul/sbv015 · Cited by 42
Can cognitive insight predict symptom remission in a first episode psychosis cohort?
O’Connor, J. A., Ellett, L., Ajnakina, O., Schoeler, T., Kollliakou, A., Trotta, A., Wiffen, B. D., Falcone, A. M., Di Forti, M., Murray, R. M., et al. (2017) · BMC Psychiatry · doi:10.1186/s12888-017-1210-9 · Cited by 37
Tago, T., & Toyohara, J. (2018) · Molecules · doi:10.3390/molecules23020300 · Cited by 28
Cited by
Machine learning enhances prediction of illness course: a longitudinal study in eating disorders
Haynos, A. F., Wang, S. B., Lipson, S., Peterson, C. B., Mitchell, J. E., Halmi, K. A., Agras, W. S., & Crow, S. J. (2021) · Psychological Medicine · doi:10.1017/s0033291720000227 · Cited by 73
Can cognitive insight predict symptom remission in a first episode psychosis cohort?
O’Connor, J. A., Ellett, L., Ajnakina, O., Schoeler, T., Kollliakou, A., Trotta, A., Wiffen, B. D., Falcone, A. M., Di Forti, M., Murray, R. M., et al. (2017) · BMC Psychiatry · doi:10.1186/s12888-017-1210-9 · Cited by 37
Shields, G. E., Buck, D., Varese, F., Yung, A. R., Thompson, A., Husain, N., Broome, M. R., Upthegrove, R., Byrne, R., & Davies, L. M. (2022) · BMC Psychiatry · doi:10.1186/s12888-022-03769-7 · Cited by 16
“People who are experiencing first-episode psychosis have variable outcomes; some patients may experience a full recovery, others may require life-long treatment [6].”
Background
Metadata
- Authors
- Suvisaari, J., Mantere, O., Keinänen, J., Mäntylä, T., Rikandi, E., Lindgren, M., Kieseppä, T., & Raij, T. T.
- Venue
- Frontiers in Psychiatry
- Publisher
- Frontiers Media SA
- Published
- 2018-11-13
- Volume
- 9
- Pages
- 580-580
- ISSN
- 1664-0640 (ISSN-L)
- OpenAlex
- W2900855407
- Cited by
- 87
- References
- 49
- FWCI
- 5.90
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.